Vaxcyte to Participate in Upcoming Investor Conferences
Vaxcyte management will attend the Leerink Partners Therapeutics Forum on July 15 and the BTIG Virtual Biotechnology Conference on July 28 to host one-on-one meetings. The clinical-stage company is advancing a pipeline of vaccines including VAX-31, a Phase 3 candidate for pneumococcal disease, and VAX-A1 for Group A Strep, utilizing its licensed XpressCF platform.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.